IP Library Granted Patent US 6,979,462
Granted Patent B1
US 6,979,462 · App. 09/690,974 · Granted Dec 27, 2005

Stabilization of solid drug formulations

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,979,462
App. No.
09/690,974
Granted
Dec 27, 2005
Kind
B1
Abstract

Pharmaceutical formulations and dosage forms are provided having improved stability to moisture-induced degradation when compared with conventional dosage forms, especially tablets. The invention features low compression forms of drugs known to be susceptible to moisture-induced degradation together with excipients, preferably in encapsulated forms. In other embodiments, relatively non-volatile oils can be admixed with the drug and/or the excipients to stabilize the formulations toward moisture-induced degradation. Hydrophobic powders are also optionally added to the formulations.

Claims (43)

1. A drug dosage form prepared by compression techniques comprising:

a substantially non-volatile, pharmaceutically acceptable oil, and

a compound susceptible to moisture-induced degradation treated with the substantially non-volatile, pharmaceutically acceptable oil to substantially waterproof the compound susceptible to moisture-induced degradation;

the drug dosage form prepared by:

(a) dispersing the compound susceptible to moisture-induced degradation in the substantially non-volatile, pharmaceutically acceptable oil; and

(b) compacting the compound susceptible to moisture-induced degradation into dosage forms using compression pressures of up to 5,000 psi/g.

2. The drug dosage form of claim 1 wherein the oil is an animal or vegetable oil.

3. The drug dosage form of claim 1 wherein said oil is olive, corn, peanut, nut, soy, rapeseed, cottonseed, vitamin E, fish, or tallow-derived oil.

4. The drug dosage form of claim 1 wherein the oil is a mineral oil or silicone oil.

5. The drug dosage form of claim 1 wherein the compound—oil admixture is present within a capsule.

6. The drug dosage form of claim 1 wherein the compound—oil admixture is present within a soft shell capsule.

7. The drug dosage form of claim 1 wherein the compound—oil admixture is present within a specially sealed hard-shell capsule.

8. The drug dosage form of claim 1 wherein at least some of the compound—oil admixture is adsorbed on a pharmaceutically acceptable excipient.

9. The drug dosage form of claim 1 wherein the excipient having the compound—oil admixture adsorbed thereupon is within a capsule.

10. The drug dosage form of claim 1 wherein the excipient having the compound—oil admixture adsorbed thereupon is within a tablet.

11. A drug dosage form prepared by compression techniques comprising:

a pharmaceutically acceptable excipient admixed with a substantially non-volatile pharmaceutically acceptable oil; and

a compound susceptible to moisture-induced degradation treated with the pharmaceutically acceptable excipient to substantially waterproof the compound susceptible to moisture-induced degradation;

wherein the drug dosage form is prepared by:

(a) dispersing the compound susceptible to moisture-induced degradation in the pharmaceutically acceptable excipient;

(b) compacting the compound susceptible to moisture-induced degradation into dosage forms using compression pressures of up to 5,000 psi/g.

12. The drug dosage form of claim 11 wherein the oil is an animal or vegetable oil.

13. The drug dosage form of claim 11 wherein said oil is olive, corn, peanut, nut, soy, rapeseed, cottonseed, vitamin E, fish, or tallow-derived oil.

14. The drug dosage form of claim 11 wherein the oil is a mineral oil or silicone oil.

15. The drug dosage form of claim 11 wherein the drug and the excipient—oil admixture are present within a capsule.

16. The drug dosage form of claim 11 wherein the drug and the excipient—oil admixture are present within a tablet.

17. A drug form prepared by compression techniques comprising:

a compound susceptible to moisture-induced degradation treated with a first pharmaceutically acceptable oil to substantially waterproof the compound susceptible to moisture-induced degradation; and

a pharmaceutically acceptable excipient admixed with a second pharmaceutically acceptable oil to substantially waterproof the pharmaceutically acceptable excipient, wherein the first pharmaceutical acceptable oil is different from the second pharmaceutically acceptable oil;

the drug dosage form prepared by:

(a) dispersing the compound susceptible to moisture-induced degradation in the pharmaceutically acceptable excipient;

(b) compacting the compound susceptible to moisture-induced degradation into dosage forms using compression pressures of up to 5,000 psi/g.

18. The drug dosage form of claim 17 wherein the first pharmaceutically acceptable oil is an animal oil and the second pharmaceutically acceptable oil is a vegetable oil.

19. The drug dosage form of claim 17 wherein the first and the second pharmaceutically acceptable oils are, independently, olive, corn, peanut, nut, soy, rapeseed, cottonseed, vitamin E, fish, or tallow-derived oil.

20. The drug dosage form of claim 17 wherein the first pharmaceutically acceptable oil is an mineral oil and the second pharmaceutically acceptable oil is a silicone oil.

21. The drug dosage form of claim 17 wherein the compound—oil admixtured and the excipient—oil admixture are present within a capsule.

22. The drug dosage form of claim 17 wherein the compound—oil admixture and the excipient—oil admixture are present within a tablet.

23. A method for administering a compound susceptible to moisture-induced degradation to a patient comprising providing a unit dose of the compound which has not been processed employing high compression.

24. A method for administering a compound susceptible to moisture-induced degradation to a patient comprising providing a unit dose of the compound admixed with a substantially non-volatile, pharmaceutically acceptable oil.

25. The method of claim 24 wherein the compound—oil admixture is present within a capsule.

26. The method of claim 24 wherein the compound—oil admixture is adsorbed on a pharmaceutically acceptable excipient.

27. A method for administering a compound susceptible to moisture-induced degradation to a patient comprising providing a unit dose of the compound and a pharmaceutically acceptable excipient admixed with a substantially non-volatile, pharmaceutically acceptable oil.

28. A method for administering a compound susceptible to moisture-induced degradation to a patient comprising providing a unit dose of the compound and at least one pharmaceutically acceptable hydrophobic powder.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 14, 2016
From: MUTUAL PHARMACEUTICAL COMPANY, INC.
To: SUN PHARMACEUTICAL INDUSTRIES, INC.
Reel/Frame 040017/0158 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 26, 2012
From: MPC OLDCO, INC.
To: MUTUAL PHARMACEUTICAL COMPANY, INC.
Reel/Frame 029526/0361 →
CHANGE OF NAME Recorded Nov 30, 2012
From: MUTUAL PHARMACEUTICAL COMPANY, INC.
To: MPC OLDCO, INC.
Reel/Frame 029377/0901 →
RELEASE OF SECURITY INTEREST Recorded Aug 12, 2011
From: UBS AG, STAMFORD BRANCH, A SWISS BANKING INSTITUTION
To: MUTUAL PHARMACEUTICAL COMPANY, INC., A PENNSYLVANIA CORPORATION
Reel/Frame 026744/0541 →